Holen Sie sich die Stockscreener-App
31.28
0.86%
-0.27
Handel nachbörslich:
31.28
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$31.55
Offen:
$31.63
24-Stunden-Volumen:
1.40M
Relative Volume:
0.75
Marktkapitalisierung:
$3.01B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-4.8346
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
+3.23%
1M Leistung:
+9.91%
6M Leistung:
-23.89%
1J Leistung:
-44.26%
1-Tages-Spanne:
$31.03
$31.92
1-Wochen-Bereich:
$29.71
$32.58
52-Wochen-Spanne:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
31.28 | 3.09B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
What earnings revisions data tells us about Ultragenyx Pharmaceutical Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
What indicators show strength in Ultragenyx Pharmaceutical Inc.2025 Institutional Moves & Detailed Earnings Play Strategies - Newser
What does recent volatility data suggest for Ultragenyx Pharmaceutical Inc.2025 Bull vs Bear & Comprehensive Market Scan Reports - Newser
How to build a dashboard for Ultragenyx Pharmaceutical Inc. stock2025 Big Picture & Safe Entry Zone Identification - Newser
Trend analysis for Ultragenyx Pharmaceutical Inc. this weekQuarterly Profit Summary & Low Drawdown Trading Techniques - Newser
How to interpret RSI for Ultragenyx Pharmaceutical Inc. stockMarket Performance Report & Long-Term Capital Growth Strategies - Newser
Real time scanner hits for Ultragenyx Pharmaceutical Inc. explainedWeekly Profit Analysis & Consistent Return Investment Signals - Newser
How hedge fund analytics apply to Ultragenyx Pharmaceutical Inc. stockShort Setup & Weekly Chart Analysis and Guides - Newser
Will earnings trigger a reversal in Ultragenyx Pharmaceutical Inc.Portfolio Value Summary & Weekly Watchlist of Top Performers - Newser
Institutional scanner results for Ultragenyx Pharmaceutical Inc.2025 Valuation Update & Precise Buy Zone Identification - Newser
Top chart patterns to watch in Ultragenyx Pharmaceutical Inc.2025 Support & Resistance & Verified Chart Pattern Trade Signals - Newser
Quantitative breakdown of Ultragenyx Pharmaceutical Inc. recent moveCEO Change & Entry Point Confirmation Signals - Newser
Ultragenyx Pharmaceutical Inc. stock trend forecastInsider Buying & Weekly Watchlist for Consistent Profits - Newser
Ultragenyx Pharmaceutical Inc. stock daily chart insightsLong Setup & Reliable Breakout Stock Forecasts - Newser
Is Ultragenyx Pharmaceutical Inc. stock good for income investorsJuly 2025 Rallies & Weekly Market Pulse Alerts - khodrobank.com
Real time pattern detection on Ultragenyx Pharmaceutical Inc. stockMarket Movement Recap & Risk Controlled Swing Trade Alerts - Newser
Can Ultragenyx Pharmaceutical Inc. ride the EV waveTrade Exit Summary & AI Optimized Trading Strategy Guides - khodrobank.com
What’s the outlook for Ultragenyx Pharmaceutical Inc.’s sectorPortfolio Growth Summary & Weekly Market Pulse Updates - khodrobank.com
Applying sector rotation models to Ultragenyx Pharmaceutical Inc.CPI Data & Proven Capital Preservation Methods - Newser
Published on: 2025-09-02 13:45:06 - Newser
What machine learning models say about Ultragenyx Pharmaceutical Inc.Earnings Trend Report & Precise Swing Trade Entry Alerts - Newser
Pomerantz LLP Investigates Claims Against Ultragenyx Pharmaceutical Inc. - AInvest
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stock2025 Market Overview & Real-Time Buy Signal Notifications - Newser
Ultragenyx Pharmaceutical Inc. recovery potential after sell offCEO Change & Daily Market Momentum Tracking - Newser
Full technical analysis of Ultragenyx Pharmaceutical Inc. stockWeekly Stock Summary & AI Forecast Swing Trade Picks - Newser
Is Ultragenyx Pharmaceutical Inc. being accumulated by smart moneyCPI Data & Weekly High Momentum Picks - khodrobank.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - Your Wyoming Link
Does Ultragenyx Pharmaceutical Inc. outperform in volatile marketsJuly 2025 Market Mood & High Accuracy Trade Alerts - خودرو بانک
Published on: 2025-09-01 02:49:16 - Newser
Published on: 2025-08-31 23:35:05 - Newser
Ultragenyx Pharmaceutical Inc. stock trendline breakdownJuly 2025 Selloffs & Accurate Technical Buy Alerts - Newser
Ultragenyx Pharmaceutical Inc. stock outlook for YEARJuly 2025 Update & High Accuracy Trade Alerts - Newser
Custom watchlist performance reports with Ultragenyx Pharmaceutical Inc.M&A Rumor & AI Driven Price Forecasts - Newser
What Fibonacci levels say about Ultragenyx Pharmaceutical Inc. reboundEarnings Miss & Weekly Watchlist of Top Performers - Newser
Applying big data sentiment scoring on Ultragenyx Pharmaceutical Inc.Quarterly Growth Report & AI Forecast Swing Trade Picks - Newser
Intraday pattern recognizer results for Ultragenyx Pharmaceutical Inc.2025 Bull vs Bear & Safe Swing Trade Setups - Newser
News impact scoring models applied to Ultragenyx Pharmaceutical Inc.Weekly Trade Report & Safe Capital Growth Trade Ideas - Newser
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):